A Smart + Strong Site
Subscribe to:
POZ magazine

Back to home » Treatment News » Top Stories

Most Popular Stories
Undetectable Viral Load Essentially Eliminates Transmission Risk in Straight Couples
FDA Approves New Single-Tablet HIV Regimen, Triumeq
Life Expectancy for Young People With HIV Is Nearly Normal
A 15-Year Jump in Life Expectancy for People With HIV
Scientists Devise Method of Snipping HIV From Immune Cells
Monkey HIV Vaccine Success Opens Door for Human Trials
HIV Combo Pill Less Toxic Thanks to New Form of Tenofovir
What's That Mean?
(just double-click it!)

If you don't understand one of the words in this article, just double-click it. A window will open with a definition from mondofacto's On-line Medical Dictionary. If the double-click feature doesn't work in your browser, you can enter the word below:

Most Popular Lessons
Aging & HIV
The HIV Life Cycle
Herpes Simplex Virus
Syphilis & Neurosyphilis
Treatments for Opportunistic Infections (OIs)
What is AIDS & HIV?
More News

Have medical or treatment news about HIV? Send press releases, news tips and other announcements to news@aidsmeds.com.

Click here for more news


April 2, 2013

FDA Approves a First-in-Class Diabetes Drug: Invokana

The U.S. Food and Drug Administration (FDA) has approved the first in a new class of medications to treat type 2 diabetes, under the condition that the drug manufacturer conduct additional research, The New York Times reports. The FDA approved Invokana (canagliflozin), which is a sodium glucose co-transporter 2 (SGLT2) manufactured by Janssen Pharmaceuticals, a division of Johnson & Johnson. Invokana is the only approved diabetes therapy that does not affect insulin. Instead, it operates by impeding glucose’s reabsorption into the kidney, which increases excretion of the sugar directly into the urine.

Type 2 diabetes disproportionately affects people living with HIV and its prevalence among this group is on the rise according to recent research.

The FDA ordered Janssen to conduct five post marketing studies: a bone safety trial; a cardiovascular outcomes study; two pediatric trials; and a program to monitor for cancers, severe pancreatitis, severe high blood pressure, sensitivity to light, liver abnormalities and adverse effects on pregnancy.

The agency granted approval for Invokana based on nine clinical trials involving more than 10,000 participants with type 2 diabetes. As compared with a placebo, the drug demonstrated improvement in fasting plasma glucose and glycated hemoglobin (HbA1c) levels. It also proved non-inferior to the diabetes medications Amaryl (glimepiride) and Januvia (sitagliptin).

Common side effects included vaginal yeast infections and urinary tract infections.

To read the New York Times story, click here.

To read the FDA release, click here.

Search: U.S. Food and Drug Administration, FDA, HIV, type 2 diabetes, The New York Times, Invokana, Janssen Pharmaceuticals, Johnson & Johnson, sodium glucose co-transporter 2, SGLT2, canagliflozin, Amaryl, glimepiride, Januvia, sitagliptin.

Scroll down to comment on this story.


(will display; 2-50 characters)


(will NOT display)


(will display; optional)

Comment (500 characters left):

(Note: The AIDSmeds team reviews all comments before they are posted. Please do not include ":" "@" "<" ">" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules

Show comments (0 total)

[Go to top]

Quick Links
About HIV and AIDS
The Cure
Lab Tests
Clinical Trials
HIV Meds
Starting Treatment
Switching Treatment
Drug Resistance
Side Effects
Hepatitis & HIV
Women & Children
Fact Sheets
Treatment News
Community Forums
Conference Coverage
Health Services Directory
POZ Magazine
AIDSmeds on Twitter

Conference Coverage

XX International AIDS Conference
(AIDS 2014)
Melbourne, Australia
July 20 - 25, 2014

21st Conference on Retroviruses and Opportunistic Infections
(CROI 2014)
Boston, MA
March 3 - 7, 2014

7th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention
(IAS 2013)
Kuala Lumpur, Malaysia
June 30 - July 3, 2013

more conference coverage

[ about AIDSmeds | AIDSmeds advisory board | our staff | advertising policy | advertise/contact us]
© 2016 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.